Genetic determinants of response to clopidogrel and cardiovascular events.
By T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, N. Meneveau, P. Steg, J. Ferrières, N. Danchin, L. Becquemont and 1 more. New England Journal of Medicine, 2009
1,763 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Hematology, Pharmacology
View Paper: https://www.semanticscholar.org/paper/2aeb2b4d1a652dc3fbbbee230d4437e57430b037
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Pharmacology
Citations in the corpus
- Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. (2013, background): “Numerous clinical studies have confirmed that CYP2C19 PMs have significantly lower anticoagulation effect of clopidogrel,which is associatedwith an increased risk of major adverse cardiovascular events (Collet et al., 2009; Mega et al., 2009; Simon et al., 2009; Sofi et al., 2011).”
- The management of antithrombotic agents for patients undergoing GI endoscopy. (2016, background): “Clopidogrel (Plavix) efficacy can be limited by variations of the ABCB13435 TT and CYP2C19 genotypes of cytochrome P450 enzymes, which alter hepatic metabolism of the clopidogrel prodrug to its active thiol metabolite.(41,42) This altered metabolism results in variable antiplatelet effects and adver”
- A population-based study of the drug interaction between proton pump inhibitors and clopidogrel (2009, background): “Patients with loss-of-function polymorphisms have lower levels of the active metabolite of clopidogrel, diminished platelet inhibition during clopidogrel treatment and an increased risk of cardiovascular events relative to those without such polymorphisms.(9,10) Given the important role of cytochrom”